Page 1

cogent BIOSCIENCES Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results May 12 , 2021 IND cleared for Phase 2 study of CGT9486 , a selective mutant KIT inhibitor , in Advanced Systemic Mastocytosis patients John Robinson , PhD appointed as Chief Scientific Officer to lead newly created Cogent Research team Evan Kearns , JD joined Cogent as Chief Legal Officer Ended Q1 2021 with $ 230.7 million in cash , sufficient to fund operations into 2024 CAMBRIDGE , Mass . and BOULDER , Colo . , May 12 , 2021 / PRNewswire / -- Cogent Biosciences , Inc. ( Nasdaq : COGT ) , a biotechnology company focused on developing precision therapies for genetically defined diseases , today announced financial results for the first quarter ended March 31 , 2021 and provided several corporate updates . cogent BIOSCIENCES " We are on track to initiate three clinical trials of CGT9486 this year , beginning with a study in Advanced Systemic Mastocytosis ( AdvSM ) patients for which we recently received IND clearance from the FDA , " said Andrew Robbins , President and CEO of Cogent Biosciences . " In parallel , we continue to make great progress building a world - class R & D organization , and I'm particularly excited to welcome John and Evan to the Cogent leadership team as I know they will make tremendous contributions toward achieving our goals . " Recent Program and Corporate Highlights • Clinical Trial Evaluating CGT9486 in Patients with Advanced Systemic Mastocytosis • The US FDA recently cleared Cogent's Investigational New Drug ( IND ) submission for a Phase 2 study , which remains on track for initiation in 1H 2021 . • Appointed John Robinson , PhD , as Chief Scientific Officer o Dr. Robinson joins the Cogent Biosciences team from Pfizer where he most recently served as Vice President , Medicinal Chemistry . For more than 15 years prior to his time at Pfizer , Dr. Robinson was a senior member of the Array BioPharma scientific leadership team , a group responsible for developing over 25 Investigational New Drug ( IND ) applications including five U.S. Food and Drug Administration ( FDA ) approved medicines : MEKTOVIⓇ ( binimetinib ) , TUKYSAⓇ ( tucatinib ) , VITRAKVI® ( larotrectinib ) , Retevmo ™ ( selpercatinib ) and Koselugo ™ ( selumetinib ) . Dr. Robinson holds a BS from Indiana University of Pennsylvania and a PhD from the University of Delaware . • Appointed Evan Kearns , JD , as Chief Legal Officer • Mr. Kearns joins Cogent with nearly 15 years of experience in the biopharmaceutical industry . Prior to joining Cogent , Mr. Kearns served as Vice President , General Counsel , Corporate Secretary and Chief Compliance Officer at Agenus Inc. , where he guided the global biopharmaceutical company through multiple clinical and preclinical programs . Previously , Mr. Kearns worked at the Boston office of Goodwin Procter LLP , where he advised both public and private companies in domestic and international transactions including corporate and securities law matters , merger , acquisition and financing transactions , and corporate governance . Mr. Kearns holds a BA from Colby College and a JD from the University of Toledo . • Announced Formation of Cogent Research Team • Based in Boulder , Colorado , the Cogent Research Team will focus on pioneering best - in - class , small molecule therapeutics to expand Cogent's pipeline and deliver novel precision therapies for patients living with unmet medical